# Asimov

> Synthetic biology platform for designing and manufacturing genetic medicines.

## Why it is interesting

Programming living cells for biologics, cell/gene therapy, RNA — MIT/BU founders with $200M+ raised.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Seed (2017): led by a16z (TechCrunch)
- Series B (2023): $175M led by CPP Investments with a16z participation (company press)
- Co-investors: no additional institutional investors in VCT directory disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/asimov